WASHINGTON — The pharmaceutical industry’s Washington lobbying group is fighting full force to scuttle a Trump administration policy proposal that would tie the price of drugs in the U.S. to their costs abroad — and making a handful of specious arguments along the way, health policy experts told STAT.

PhRMA has launched a multipronged attack against the proposal, arguing that it would, in effect, make health care in America more closely resemble systems in Europe. Patients wouldn’t be able to get as many new drugs and might suffer as a result, they say.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • The above critiques are straw man arguments, but it would be great to further report on legitimate critiques.

    Specifically, the opinion piece, written on this website a week or so ago, titled “Drug Pricing Conversations Must Include the Cost of Innovation”, is a very clear description of the trade-offs at hand. STATNews can be a place for informative conversations around these real trade-offs, not just in opinion pieces, but pressing those who try to ignore those trade-offs (politicians, policy makers, advocates) for on-the-record acknowledgement of these facts.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy